Even though it was reported that 90% of esophageal cancer show EGFR upregulation [35] and a recent meta-analysis found EGFR overexpression to be a predictive biomarker in clinical practice (because of its correlation with the clinicopathological features and overall survival prognostic value [36]), our study revealed no differences in EGF and EGFR mRNA expressions in esophageal tissues with or without endoscopically visible pathological changes in GERD patients. This evidence concerns the gene EGF and esophageal cancer.